{
    "question":{
        "0":"What is the definition of anterior open bite and what are some causes of anterior open bite?",
        "1":"How does the morphology of the maxillary arch relate to the etiology of anterior open bite?",
        "2":"What are some conventional orthodontic treatments for correcting anterior open bite?",
        "3":"How will the effectiveness of the treatment for anterior open bite be assessed in the study mentioned in the Maxillary Intrusive Force by Temporary Anchorage Devices report?",
        "4":"What specific techniques will be employed in the treatment plan to address the anterior open bite problem, as outlined in the Maxillary Intrusive Force by Temporary Anchorage Devices report?",
        "5":"What are the distinguishing clinical features of CMT4J, and how do they differentiate it from other neuropathies such as CIDP and Guillain-Barre Syndrome?",
        "6":"How does the proposed natural history and outcome measure discovery study of CMT4J intend to contribute to the understanding of the disease's progression and potential treatment?",
        "7":"Why are natural history studies deemed essential in the context of rare diseases like CMT4J, especially concerning the development of therapeutic interventions?",
        "8":"How do the objectives of the CMT4J natural history and outcome measure discovery study align with the broader goals of rare disease research and therapeutic development?",
        "9":"What procedures were involved in preparing dendritic cell vaccines for the Vaccination of Melanoma Patients clinical trial?",
        "10":"What challenges must be addressed to enhance the effectiveness of cellular vaccine-based immunotherapy?",
        "11":"How does the proposed optimization of the Vaccination of Melanoma Patients clinical protocol aim to improve the efficacy of dendritic cell vaccines?",
        "12":"What evaluation methods were employed before and after the Multi Joint Isokinetic Training treatment, and what parameters were assessed?",
        "13":"What are the specific indications for use of the Accufit Electrical Muscle Stimulation device mentioned in the clinical trial protocol for muscle toning, and how does it achieve its intended effects?",
        "14":"In the context of potential risks associated with muscle electrical stimulation treatment, how does the clinical trial protocol plan to mitigate these risks, particularly concerning adverse events such as transient tenderness and skin burns?",
        "15":"What are the contraindications outlined in the clinical trial protocol regarding the usage of the Accufit Electrical Muscle Stimulation device, and what potential complications could arise if these contraindications are not adhered to?",
        "16":"What is the objective of the \"Postprandial Ambulation in Gestational Diabetes\" trial, and how does it aim to address the challenges associated with gestational diabetes?",
        "17":"How is the \"Postprandial Ambulation in Gestational Diabetes\" trial designed, and what are the key components of its methodology?",
        "18":"What measures are in place to ensure the reliability and validity of data collected in the \"Postprandial Ambulation in Gestational Diabetes\" trial, and how does it adhere to standard clinical care practices?",
        "19":"How does the national variation in day-case rates for TURBT, TURP, and TUEP surgeries impact patient access and experience across different hospitals in England?",
        "20":"What factors contribute to the observed trends of increasing day-case rates for TURBT, TURP, and TUEP surgeries in England over the past five years?",
        "21":"How might qualitative research on patient experiences following day-case TURBT, TURP, and TUEP surgeries inform future GIRFT recommendations and healthcare policies regarding optimal day-case surgery pathways?"
    },
    "answer":{
        "0":"Anterior open bite may be defined as a condition where the upper incisor crowns fail to overlap the incisal third of the lower incisor crowns when the mandible is brought into full occlusion. Causes of anterior open bite include hereditary or non-hereditary origins acting pre and post-natally on the tissues of the orofacial region, with factors often being a combination of many that are within each individual's inherent growth potential.",
        "1":"The morphology of the maxillary arch relates to the etiology of anterior open bite by showing characteristic features that are associated with the underlying causes. For instance, if an anterior open bite is due to a foreign body being held passively between incisor teeth or due to thumb sucking habit, it may result in localized failure for certain teeth to erupt fully and contribute to a specific shape of the maxillary arch.",
        "2":"Some conventional orthodontic treatments for correcting anterior open bite include:\n\n- Bite blocks,\n\n- High-pull headgear, and new facemask designs.\n\n- Fixed mechanics like multiloop edgewise archwires,\n\n- Extraction therapy,\n\n- Intermaxillary vertical elastics,\n\n- Inhibition of molar eruption during growth.\n\nThese treatments aim to achieve dentoalveolar intrusion of the maxillary posterior segments but may have negative effects on skeletal and esthetic patterns with a tendency for relapse.",
        "3":"The effectiveness of the treatment for anterior open bite in the study \"Evaluation Treatment Outcomes of Anterior Open Bite Treated with Maxillary Intrusive Force by Temporary Anchorage Devices\" will be assessed using a paired t-test. A minimum total sample size of 10 participants is calculated to detect an effect size of 0.9 with 80% power at a significance level of p<0.05, as determined by G*Power software version 3.1.9.3.",
        "4":"The study aims to evaluate the treatment outcome of an anterior open bite using temporary anchorage devices (TADs), specifically buccal and palatal miniscrews, for maxillary intrusion. The technique involves placing TADs to intrude the maxillary posterior teeth, facilitating auto rotation of the mandible to close the anterior open bite. Additionally, changes in dentofacial structures through molar and buccal segment intrusion with miniplates placed in the zygoma have been previously reported as successful methods for similar treatments (12-13).",
        "5":"The distinguishing clinical features of Charcot-Marie-Tooth Disease Type 4J (CMT4J) include childhood onset gait abnormalities, poor balance, accelerated limb weakness, and muscle atrophy affecting distal and proximal musculature. These symptoms often progress rapidly during teen or adult years. CMT4J differs from other neuropathies such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Guillain-Barre Syndrome in that it typically presents an acute or subacute onset, which may mimic the symptoms of acquired neuropathies. Additionally, sensory symptoms are minimal but can include decreased responsiveness to touch, pinprick, or vibration distally. Bulbar and cranial nerve functions are often spared in CMT4J, unlike some presentations of Guillain-Barre Syndrome where these may be affected. Intellect is often normal in individuals with CMT4J.",
        "6":"The proposed study intends to contribute by longitudinally collecting standardized clinical data from subjects with a molecularly confirmed diagnosis of CMT4J. This will aid in evaluating epidemiological characteristics, clinical course, and identifying outcome measures for future clinical trials. The comprehensive collection of various assessments including neurological exams, imaging studies, and genetic information is expected to enhance understanding of the disease's progression and inform potential treatments through better-defined outcome measures.",
        "7":"Natural history studies are critical for understanding the progression of rare diseases such as Charcot-Marie-Tooth Disease Type 4J (CMT4J) because they track the disease's course over time without intervention. This longitudinal data provides a baseline to evaluate how therapeutic interventions perform against the natural progression of the disease, allowing researchers and clinicians to gauge effectiveness and tailor treatments appropriately.\n\n\nAdditionally, for rare conditions like CMT4J with limited prevalence, it's challenging to gather large samples quickly. Natural history studies enable a deeper insight into the phenotypic spectrum of the disease across diverse populations, which is essential when developing targeted therapies and understanding potential variability in clinical presentation and progression among different patients.\n\n\nNatural history studies also offer an opportunity for identifying biomarkers and outcome measures that may predict disease trajectory or therapeutic response, aiding in personalized medicine approaches. This information is vital when considering the long-term commitment required from patients with rare diseases, as it can inform expectations and help manage care over extended periods.\n\n\nFurthermore, such studies contribute to building international collaborative networks that share knowledge about these conditions, which is especially important for rare diseases where patient populations are scattered globally. This collective effort accelerates the discovery of effective interventions by pooling resources and expertise.\n\n\nLastly, they facilitate regulatory processes by providing comprehensive data on disease progression that can be used to support approvals for new therapies designed specifically for rare diseases like CMT4J. This is particularly crucial when dealing with conditions where the therapeutic window and potential side effects are not well understood due to limited patient samples and prior research focus.",
        "8":"The objectives of the CMT4J natural history and outcome measure discovery study are well-aligned with the broader goals of rare disease research and therapeutic development. Specifically, they aim to:\n\n1. Improve understanding of the course and phenotypic spectrum of CMT4J (objective 1.4). This knowledge is crucial for establishing a foundation upon which future therapies can be developed.\n\n2. Explore genetic-phenotype correlations to allow better prediction of disease progression based on genetic information (objective 1.4). This aligns with the goal of using genomic data in rare diseases to personalize and optimize treatment strategies.\n\n3. Evaluate candidate clinical trial outcome measures related to various aspects, including motor function, quality of life, radiology, and electrophysiology (objective 1.4). This aligns with the goal of identifying appropriate endpoints for rare disease trials that can lead to meaningful therapeutic advancements.\n\n4. Facilitate access to new therapies by providing a comprehensive understanding of CMT4J and its impact on patients (objective 1.4). This supports the broader goal of translating research findings into clinical applications that benefit patient populations with rare diseases like CMT4J.\n\nOverall, these objectives contribute to advancing knowledge about CMT4J and enhancing therapeutic development for this and other rare diseases.",
        "9":"In the context provided, specific details about the procedures used in preparing dendritic cell vaccines for the Vaccination of Melanoma Patients phase II study are not directly mentioned. However, generally speaking, dendritic cell vaccine preparation involves several key steps:\n\n1. Isolation and culture: Dendritic cells (DCs) are typically isolated from a patient's blood or bone marrow using specific antibodies that target immature DC markers like CD14+CD36-.\n\n2. Maturation: The isolated DCs are then cultured in vitro with maturation stimuli such as TLR ligands, cytokines (e.g., GM-CSF), and IL-4 to enhance their antigen presentation capabilities.\n\n3. Antigen loading: Peptides or tumor lysates specific to the patient's melanoma are introduced into the mature DCs for uptake. The provided context mentions \"peptide- or tumor lysate-pulsed dendritic cells,\" which align with this step.\n\n4. Expansion and quality control: Cultured DC vaccines may be further expanded, followed by testing to ensure their purity, potency, and ability to activate T-cells\u2014this is critical for the clinical efficacy of dendritic cell vaccines.\n\n5. Dosing and administration: The prepared DC vaccine formulations are then administered to patients in conjunction with adjuvants or other immune stimulatory agents, as seen by the mention of low-dose interleukin-2 (IL-2) in the study context.\n\nPlease note that these general steps may vary depending on specific trial protocols and advancements in dendritic cell vaccine technology.",
        "10":"To enhance the effectiveness of cellular vaccine-based immunotherapy, it is crucial to address obstacles related to tumor heterogeneity and antigenic expression. Additionally, strategies should be developed to counteract tumors' escape mechanisms, such as inhibiting antigen presentation or producing immunosuppressive substances like TGF-beta and IL-10.",
        "11":"The optimization of the Vaccination of Melanoma Patients clinical protocol aims to improve the efficacy of dendritic cell (DC) vaccines by combining them with subsequent immunotherapy based on dendritic cells pulsed with anti-idiotypic antigens, which has shown promising results in treating minimal residual disease. Specifically, 8 out of 11 treated patients were able to eliminate residual malignant cells after vaccination (Escobar et al., Clin. Exp. Immunol.). Additionally, the protocol takes into account the need for a more cost-effective approach by using DCs loaded with allogeneic melanoma extracts in a phase I clinical trial conducted in Chile, addressing the limitations of chemotherapy and radiotherapy commonly used in advanced malignant melanoma cases.",
        "12":"Before and after the Multi Joint Isokinetic Training treatment, subject satisfaction was evaluated using a Satisfaction Survey at each follow-up visit. The efficacy of muscle strength improvements post-treatment were assessed by measuring increases in muscle strength as indicated on a dynamometer compared to baseline measurements. Additionally, the reduction in core circumference was measured using the Seca Circumferential System and compared with baseline values. Photographic evaluation for primary endpoint involved an independent, blinded reviewer identifying correctly pre-treatment baseline images when compared to post-treatment images taken at follow-up visits.",
        "13":"The specific indications for use of the Accufit Electrical Muscle Stimulation device as mentioned in the clinical trial protocol include relaxation of muscles, muscle re-education, reduction of pain, and increased local blood circulation. It achieves these intended effects by delivering electrical current flow through the muscles, which activates them to produce contraction and thereby assist in muscle toning and strengthening as per their design for muscle stimulation.\n",
        "14":"The clinical trial protocol plans to mitigate risks like transient tenderness and skin burns by conducting procedures with an experienced investigator in the therapeutic area. The investigator will be trained on device usage by the sponsor, ensuring proper application of electrical stimulation. Additionally, patients are rigorously screened before enrollment and followed throughout the study to manage adverse events effectively.\n\n\n-------",
        "15":"The contraindications for using the Accufit Electrical Muscle Stimulation device include avoiding use on the pectoral area or patients with a cardiac pacemaker, implanted defibrillator, or other metallic\/electronic devices. Not adhering to these contraindications could lead to serious complications such as injury from electrical interference with medical devices (e.g., disruption of cardiac function) and skin burns due to the presence of metal fragments in individuals who are not screened properly, like welders or metal workers.\n\n\nIf these contraindications are ignored, patients may experience adverse events including localized tenderness, erythema (skin redness), edema (swelling), discomfort, muscle burns, skin hyperpigmentation (darkening of the skin), hypopigmentation (lightening of the skin), blistering, and irregularities in skin laxity. Additionally, there could be severe consequences for patients with implanted devices if they experience electrical interference or heating due to stimulation.\n\n\nIt's important to note that subjects undergo rigorous screening before enrollment into the study to mitigate these risks and ensure patient safety during the clinical trial of the Accufit device.",
        "16":"The objective of the \"Postprandial Ambulation in Gestational Diabetes\" trial is to assess whether postprandial ambulation can decrease neonatal birth percentile as compared to patients who do not engage in postprandial ambulation. It aims to address challenges associated with gestational diabetes by potentially reducing the risk of large for gestational age (LGA) neonates, which are linked to maternal hyperglycemia after meals.\n\n\n------",
        "17":"The \"Postprandial Ambulation in Gestational Diabetes\" trial is a randomized controlled study with two groups: an intervention group that walks for 20 minutes after meals and a non-intervention group that continues their routine activities. Randomization occurs via computer-generated block randomization of ten participants at a time, and all patients diagnosed with gestational diabetes mellitus (GDM) are eligible to participate. Both groups receive glucometers and diabetic supplies, nutrition counseling, and Bluetooth enabled pedometers.",
        "18":"The document provided outlines that participants will be equipped with Bluetooth-enabled pedometers as part of their participation. However, there is no specific mention about measures directly ensuring the reliability and validity of data collected in relation to postprandial ambulation's effect on birth weight percentile within gestational diabetes patients or adherence to standard clinical care practices based on the given excerpts. Therefore, I don't have information regarding these specific measures from the provided context.",
        "19":"The national variation in day-case rates for transurethral resections of bladder tumour (TURBT), prostate resection (TURP), and transurethral enucleation of the prostate (TUEP) across different hospitals impacts patient access by potentially offering quicker recovery times, reduced hospital stays, and more convenient scheduling. However, this variation can also lead to inconsistencies in patients' experiences due to differences in care pathways, resources available at each institution, and the level of expertise among staff performing these procedures. Research is needed to identify factors contributing to favorable or unfavorable patient experiences that could inform improvements in day-case surgery development and standardization across England.\n\n\n-----",
        "20":"The document provided does not explicitly state which specific factors contribute to the increasing day-case rates. However, it is implied that various elements such as national quality improvement initiatives like the GIRFT programme's \"day -case by default\" approach and the ongoing analysis of care pathways across different hospitals may have played a role in these trends. To get detailed information about specific factors, one would need to refer to additional research or reports that examine the changes in clinical practices and healthcare policies over time within England's NHS system. Therefore, based on the provided context:\n\n\nI don't have information on the precise factors contributing to the trends of increasing day-case rates for TURBT, TURP, and TUEP surgeries in England over the past five years.",
        "21":"Qualitative research can provide in-depth insights into patients' lived experiences after undergoing day-case TURBT, TURP, and TUEP surgeries. By capturing the subjective aspects of recovery through interviews or focus groups, healthcare professionals can identify common themes that contribute to positive or negative patient experiences. This knowledge could be pivotal in shaping GIRFT (Government Instigated Review of Treatments) recommendations and healthcare policies by:\n\n\n1. Identifying areas for improvement within the current day-case surgery pathways, such as discharge planning, pain management, or postoperative support services.\n\n2. Understanding patient preferences regarding home recovery versus inpatient care settings, which may influence policy decisions related to resource allocation and infrastructure development.\n\n3. Evaluating the impact of healthcare system factors (e.g., wait times for surgery, communication between hospital staff and patients) on patient satisfaction and outcomes.\n\n4. Informing best practices that could be standardized across hospitals to ensure consistency in care quality and enhance overall patient experiences with day-case surgeries.\n\n5. Shaping educational programs for healthcare providers by highlighting the importance of empathetic communication, informed consent, and comprehensive discharge instructions tailored to patients' needs postoperatively.\n\n6. Encouraging a shift towards more patient-centered care models that integrate feedback from day-case surgery experiences into continual process improvements in healthcare delivery.\n\n\nBy integrating qualitative findings with quantitative data, GIRFT recommendations can become well-rounded and reflective of the realities faced by patients undergoing these procedures. This comprehensive approach would ultimately contribute to optimizing day-case surgery pathways for better patient outcomes and system efficiencies within healthcare policies."
    },
    "ground_truth":{
        "0":"Anterior open bite is defined as a condition where the upper incisor crowns do not overlap the incisal third of the lower incisor crowns when the jaw is fully closed. Anterior open bite can result from various causes, including hereditary or non-hereditary factors acting either before or after birth. These causes can be singular or a combination of factors influencing the growth potential of each individual patient.",
        "1":"The shape of the maxillary arch can exhibit characteristic features depending on the cause of the anterior open bite. For example, if the malocclusion is due to habits like thumb sucking or foreign objects between teeth, distinct arch shapes such as V-shaped or localized open bites may occur.",
        "2":"Conventional treatments include the use of bite blocks, high-pull headgear, new facemask designs, fixed mechanics, multiloop edgewise archwires, extraction therapy, intermaxillary vertical elastics, and inhibition of molar eruption during growth.",
        "3":"The effectiveness of the treatment will be evaluated through a comprehensive set of assessments, including panoramic and cephalometric X-rays, upper and lower orthodontic casts, extraoral and intraoral photographs. Specifically, cephalometric analysis will be conducted before and after treatment to measure parameters such as ANB angle, anterior and posterior facial heights, upper incisor inclination, and the relationship of these structures to reference lines like SN line and FH line. Additionally, smile analysis will be performed post-correction to assess the aesthetic outcomes of the treatment.",
        "4":"The treatment plan involves a multifaceted approach to correct the anterior open bite. Firstly, causative habits will be eliminated using properly selected appliances. Secondly, the open bite will be corrected through dental interventions, focusing on intruding posterior teeth using temporary anchorage devices (TADs) with miniscrews placed on both buccal and palatal sides, along with intrusive force. Finally, a smile analysis will be conducted post-correction to evaluate the effects of intrusion on aesthetics.",
        "5":"CMT4J is characterized by childhood onset gait abnormalities and balance difficulties, rapidly progressing to muscle weakness and atrophy during the teen or adult years. Its onset can mimic acquired neuropathies and is often misdiagnosed as CIDP or a subacute presentation of Guillain-Barre Syndrome. Although sensory symptoms are minimal, examination may reveal decreased response to touch, pin prick, or vibration distally. Notably, bulbar and cranial nerve functions are often spared, and intellect is typically normal.",
        "6":"The natural history study plans to enroll 20 subjects with molecularly confirmed CMT4J diagnosis and follow them longitudinally. By collecting standardized clinical data annually, including physical\/neurological exams, laboratory tests, outcome measures, neuropsychological assessments, nerve conduction studies, and imaging studies, researchers aim to elucidate epidemiological characteristics, clinical course, and identify potential outcome measures for future clinical trials. This longitudinal approach is crucial for comprehensively understanding disease progression and assessing the efficacy of potential therapies over time.",
        "7":" Natural history studies are indispensable for rare diseases like CMT4J, primarily because they provide crucial baseline data on disease progression, phenotypic variability, and prognosis. Understanding the natural course of the disease is fundamental for the development of effective therapeutic interventions. Additionally, these studies facilitate the identification of appropriate outcome measures and endpoints for clinical trials, aiding in the assessment of treatment efficacy. By comprehensively characterizing the disease trajectory, natural history studies lay the groundwork for designing targeted and successful therapeutic interventions.",
        "8":"The objectives of the CMT4J natural history study align with the broader goals of rare disease research and therapeutic development by aiming to gain a better understanding of the disease course, explore genotype-phenotype correlations, and evaluate candidate clinical trial outcome measures. By elucidating the disease's natural history and identifying predictive markers of disease progression, researchers can expedite the development and access to new therapies for rare conditions like CMT4J. Additionally, by establishing reliable outcome measures, the study facilitates the efficient evaluation of potential treatments, ultimately advancing therapeutic development and improving patient outcomes.",
        "9":"The preparation of dendritic cell vaccines involved several steps. Initially, approximately 1.8x10^8 peripheral blood mononuclear cells (PBMCs) were isolated and incubated for two hours. The resulting peripheral blood lymphocytes (PBLs) were frozen for later use, while the adherent monocytes were incubated for seven days with IL-4 and GM-CSF. On the sixth day, dendritic cells (DCs) were pulsed with tumor extracts from allogeneic melanoma cell lines and matured with TNF-alpha for 12 to 18 hours. The mature DCs were then characterized by flow cytometry and subcutaneously injected into patients.",
        "10":"Several challenges must be addressed to enhance the effectiveness of cellular vaccine-based immunotherapy. These include overcoming immunosuppression in patients due to factors like tumor burden or chemotherapy, considering the heterogeneity of antigenic expression in tumors, and tackling tumor evasion of immune system recognition through various mechanisms such as inhibiting antigen presentation or producing immunosuppressive substances like TGF-beta and IL-10.",
        "11":"The proposed optimization of the clinical protocol aims to improve the efficacy of dendritic cell vaccines by combining them with low doses of IL-2. This approach is based on studies demonstrating improved responses when dendritic cell vaccines are combined with IL-2. By using low doses of IL-2, which have fewer severe adverse effects compared to high doses, the protocol seeks to enhance the ability of dendritic cells to induce an immune response without significantly impacting patients' quality of life.",
        "12":"Lower limb motor function was assessed using the Fugl Meyer method, evaluating total lower limb motor score, total balance score, muscle strength, muscle tone, motor function, and self-care ability. Peak torque (PT) at an angular velocity of 60 \u00c2\u00b0\/s was recorded, as it represents the maximum muscle force generated during muscle contraction. Additionally, a satisfaction questionnaire survey was conducted to assess patient comfort, satisfaction, and treatment effectiveness, along with therapist statistics on operability and learning curve.",
        "13":"The Accufit Electrical Muscle Stimulation device is indicated for relaxation of muscles, muscle re-education, reduction of pain, and increased local blood circulation. It employs magnet-based and direct muscle stimulation to generate current flow through the muscles, activating them through interferential and biphasic waveforms.",
        "14":"The protocol aims to mitigate risks by conducting procedures under the supervision of an investigator experienced in the therapeutic area, who is trained by the sponsor on device usage. Furthermore, the device incorporates safety mechanisms, patients undergo rigorous screening before enrollment, and they are closely monitored throughout the study duration.",
        "15":"The protocol specifies contraindications such as avoiding use on the pectoral area, patients with cardiac pacemakers or implanted metallic\/electronic devices, undiagnosed pain syndromes, and ischemic tissues in individuals with vascular disease. Failure to adhere to these contraindications could lead to serious complications such as interference with cardiac devices or exacerbation of underlying conditions.",
        "16":"The objective of the trial is to assess the impact of postprandial ambulation on birth weight in patients with gestational diabetes compared to routine activity. It aims to address the challenges of gestational diabetes, particularly postprandial hyperglycemia, which is linked to adverse clinical outcomes such as increased birth weight and large for gestational age neonates.",
        "17":"The trial is a randomized controlled study where patients with gestational diabetes are divided into two groups: an intervention group performing 20 minutes of postprandial walking after meals, and a non-intervention group maintaining routine activity. Randomization occurs through computer-generated processes, and participants are provided with activity monitors and glucometers. Counseling, monitoring, and data collection are conducted regularly to track outcomes.",
        "18":"The trial ensures data reliability and validity through regular touchpoints with diabetic nurse educators, weekly or biweekly review of glucose and activity logs, and consistent counseling for both groups. Participants receive standard exercise counseling and glucose management, with decisions regarding insulin therapy left to medical discretion. Delivery data, including routine postpartum laboratory data, are collected to comprehensively evaluate outcomes.",
        "19":"The significant diversity in day-case rates across England for transurethral resection of bladder tumor (TURBT), transurethral resection of prostate (TURP), and transurethral enucleation of prostate (TUEP) surgeries directly affects patient access and experience. Patients may face differing levels of convenience, cost-effectiveness, and environmental impact based on whether day-case pathways are established in their treating hospitals.",
        "20":"Several factors influence the upward trajectory of day-case rates for TURBT, TURP, and TUEP surgeries in England. These may include initiatives such as the Getting It Right First Time (GIRFT) programme advocating for day-case adoption, increased focus on efficient resource utilization amidst healthcare challenges, and evolving patient preferences for home-based recovery. Additionally, advancements in medical technology and procedural techniques might also play a role in expanding the scope of day-case surgeries.",
        "21":"Qualitative research aimed at understanding patient experiences post day-case TURBT, TURP, and TUEP surgeries can offer invaluable insights into optimizing healthcare policies and recommendations. By identifying common themes and factors affecting patient experiences, such research can inform the development of more patient-centered day-case pathways. These insights can contribute to refining existing guidelines, enhancing quality of care, and ensuring that day-case surgeries align with patient needs and preferences as advocated by initiatives like GIRFT."
    },
    "contexts":{
        "0":[
            "1 \n Introduction  \n \n           Anterior open bite may be defined as: That condition where the upper \nincisor crowns fail to overlap the incisal third of the lower incisor crowns when the \nmandible is brought into full occlusion. Within the limits of this definition, the \ndegree or severity of malocclusion may vary from a mild edge to edge relationship \nof the incisor teeth to a severe and handicapping malocclusion(1). \n \n            This type of malocclusion like any other malocclusion is the result of \ncertain causes either of hereditary or non -hereditary origin that act pre - or post -\nnatally on the tissues of the orofacial region. Few malocclusions have a single \nspecific cause. more often they are the result of a combination of many factors \noperating within the inherent predetermined growth potential of each individual \npatient(2). \n \n             Morphology of Dental Open Bite : the shape of the maxillary arch will \nshow characteristic features related to the etiology .\n\nSOURCE: Evaluation Treatment Outcomes of Anterior Open Bite Treated with Maxillary Intrusive Force by Temporary Anchorage Devices..pdf",
            "3 \n  \n               The conventional orthodontic treatments for the correction of an anterior \nopen bite include bite blocks ,high-pull headgear, and new facemask designs . to \nachieve dentoalveolar intrusion of the maxillary posterior segments. Fixed \nmechanics, multiloop edgewise archwires, extraction therapy, intermaxillary \nvertical elastics, and inhibition of molar eruption during growth have also been \nused to treat the anterior open bite. (8-10). \n \n                These modalities have been recommended for intrusion of the maxillary \nposterior segment and anterior dentoalveolar extrusion. However, none of these \ntreatment approaches are satisfactory because of negative effects on the skeletal \nand\/or esthetic pattern and a serious tendency for relapse (11). \n             \n                Recently, dental implants, miniplates, and miniscrews have been used as \nanchorage units in orthodontic  treatments . These techniques can supply  the \nanchorage that is needed for specific dental movements, regardless of patient \ncooperation.\n\nSOURCE: Evaluation Treatment Outcomes of Anterior Open Bite Treated with Maxillary Intrusive Force by Temporary Anchorage Devices..pdf",
            "Cephalometric appraisal of the open bite case. \nAnOrthodonti. 2018 ;34: fl5 -72. \n \n6. Alexander CD . Open bite, dental alveolar protrusion, Class I malocclusion: \na successful treatment result. Am J Orthod Dentofacial  orthop; \n2012 ;116:494 -500. \n \n7.  Alcan T, Keles A, Erverdi N . The effects of a modified protraction \nheadgear on maxilla. Am J Orthod Dentofacial . Ortho  p 2011;117: 27 -38. \n \n8. Kim YH . Anterior open  bite and its treatment with multiloop edgewise \narchwire. Angle Orthod . 2012 ;57:290 -21.\n\nSOURCE: Evaluation Treatment Outcomes of Anterior Open Bite Treated with Maxillary Intrusive Force by Temporary Anchorage Devices..pdf"
        ],
        "1":[
            "Morphology of Dental Open Bite : the shape of the maxillary arch will \nshow characteristic features related to the etiology . If the malocclusion is due to a \nforeign body (pencil, pipe) being held passively between the incisor teeth, then the \nopen bite is localized to the particular teeth involved; they will fail to erupt to the \nocclusal level of the other teeth in the arch.  \n \n               The same clinical appearance is evident in cases having ankylosed upper \nor lower incisor teeth. When the malocclusion is as a result of a thumb sucking \nhabit, then the upper incisor teeth may be proclined resulting in a V -shaped upper\n\nSOURCE: Evaluation Treatment Outcomes of Anterior Open Bite Treated with Maxillary Intrusive Force by Temporary Anchorage Devices..pdf",
            "1 \n Introduction  \n \n           Anterior open bite may be defined as: That condition where the upper \nincisor crowns fail to overlap the incisal third of the lower incisor crowns when the \nmandible is brought into full occlusion. Within the limits of this definition, the \ndegree or severity of malocclusion may vary from a mild edge to edge relationship \nof the incisor teeth to a severe and handicapping malocclusion(1). \n \n            This type of malocclusion like any other malocclusion is the result of \ncertain causes either of hereditary or non -hereditary origin that act pre - or post -\nnatally on the tissues of the orofacial region. Few malocclusions have a single \nspecific cause. more often they are the result of a combination of many factors \noperating within the inherent predetermined growth potential of each individual \npatient(2). \n \n             Morphology of Dental Open Bite : the shape of the maxillary arch will \nshow characteristic features related to the etiology .\n\nSOURCE: Evaluation Treatment Outcomes of Anterior Open Bite Treated with Maxillary Intrusive Force by Temporary Anchorage Devices..pdf",
            "Cephalometric appraisal of the open bite case. \nAnOrthodonti. 2018 ;34: fl5 -72. \n \n6. Alexander CD . Open bite, dental alveolar protrusion, Class I malocclusion: \na successful treatment result. Am J Orthod Dentofacial  orthop; \n2012 ;116:494 -500. \n \n7.  Alcan T, Keles A, Erverdi N . The effects of a modified protraction \nheadgear on maxilla. Am J Orthod Dentofacial . Ortho  p 2011;117: 27 -38. \n \n8. Kim YH . Anterior open  bite and its treatment with multiloop edgewise \narchwire. Angle Orthod . 2012 ;57:290 -21.\n\nSOURCE: Evaluation Treatment Outcomes of Anterior Open Bite Treated with Maxillary Intrusive Force by Temporary Anchorage Devices..pdf"
        ],
        "2":[
            "3 \n  \n               The conventional orthodontic treatments for the correction of an anterior \nopen bite include bite blocks ,high-pull headgear, and new facemask designs . to \nachieve dentoalveolar intrusion of the maxillary posterior segments. Fixed \nmechanics, multiloop edgewise archwires, extraction therapy, intermaxillary \nvertical elastics, and inhibition of molar eruption during growth have also been \nused to treat the anterior open bite. (8-10). \n \n                These modalities have been recommended for intrusion of the maxillary \nposterior segment and anterior dentoalveolar extrusion. However, none of these \ntreatment approaches are satisfactory because of negative effects on the skeletal \nand\/or esthetic pattern and a serious tendency for relapse (11). \n             \n                Recently, dental implants, miniplates, and miniscrews have been used as \nanchorage units in orthodontic  treatments . These techniques can supply  the \nanchorage that is needed for specific dental movements, regardless of patient \ncooperation.\n\nSOURCE: Evaluation Treatment Outcomes of Anterior Open Bite Treated with Maxillary Intrusive Force by Temporary Anchorage Devices..pdf",
            "Cephalometric appraisal of the open bite case. \nAnOrthodonti. 2018 ;34: fl5 -72. \n \n6. Alexander CD . Open bite, dental alveolar protrusion, Class I malocclusion: \na successful treatment result. Am J Orthod Dentofacial  orthop; \n2012 ;116:494 -500. \n \n7.  Alcan T, Keles A, Erverdi N . The effects of a modified protraction \nheadgear on maxilla. Am J Orthod Dentofacial . Ortho  p 2011;117: 27 -38. \n \n8. Kim YH . Anterior open  bite and its treatment with multiloop edgewise \narchwire. Angle Orthod . 2012 ;57:290 -21.\n\nSOURCE: Evaluation Treatment Outcomes of Anterior Open Bite Treated with Maxillary Intrusive Force by Temporary Anchorage Devices..pdf",
            "7 \n 1) The following record will be taken for each patient  before delivery appliance \nand after the appliance removal  to detect amount closing of bite achieved : \n\u2212 Panoramic and cephalometric X -ray :cephalometric analysis will do \nbefore  and after treatment to detect :ANB Angel , anterior facial hight \n, posterior facial hight, upper incisor inclination ,  SN line ,FH line  . \n\u2212 Upper and lower orthodontic cast  \n\u2212 Extraoral and intraoral photograph  \n \n2) Treatment plan:  \n-eliminate  causative habit  by proper selected appliance . \n- dental correction of the open bite problem : \n\u2022 Correct the open bite by intrusion  posterior teeth with  temporary \nanchorage device , miniscrow s on buccal and palatal side and intrusive \nforce . \n\u2022 Smile analysis  will do after correction the open bite to evaluate effect \nof intrusion  .\n\nSOURCE: Evaluation Treatment Outcomes of Anterior Open Bite Treated with Maxillary Intrusive Force by Temporary Anchorage Devices..pdf"
        ],
        "3":[
            "4 \n Aim of the study  \n \nThe present study will be performed to: \n              Evaluate the treatment outcome of anterior open bite by temporary \nanchorage device TADs ( buccal and palatal miniscrows ).\n\nSOURCE: Evaluation Treatment Outcomes of Anterior Open Bite Treated with Maxillary Intrusive Force by Temporary Anchorage Devices..pdf",
            "Evaluation  Treatment  Outcomes  of Anterior Open Bite  \nTreated with Maxillary Intrusive Force by  Temporary \nAnchorage Devices . \n \nA proposal  \nSubmitted to the Faculty of Dental Medicine for Girls, Al - Azhar University  \n In Partial Fulfillment of the Requirement for Master Degree  \n \nIn \n Orthodontics  \n \nBy \nBaian  Mohammed S aaid Saaidi  \nBDS (2009 ), Faculty of Dental  Medicine  misr university for science and \ntechnology(MUST)  \n \nOrthodontic Department  \nFaculty of Dental Medicine for Girls  \nAl-Azhar University  \n16 August  2021\nCode  \nORTHO -109-2-G\n\nSOURCE: Evaluation Treatment Outcomes of Anterior Open Bite Treated with Maxillary Intrusive Force by Temporary Anchorage Devices..pdf",
            "5 \n Subjects  and Methods  \n \nSample size calculation : \nTo assess the treatment outcome of anterior open bite through a temporary \nanchorage devices TADs , paired t -test to will be used. A minimum total sample \nsize of 10 participants will be sufficient to detect the effect size of 0.9  a power (1 -\n\u03b2=0.80) of 80% at a significance probability level of  p<0.05. The sample size was \ncalculated according to G*Power software version 3.1.9.3.  \n \nFigure 1. Paired T-test- total sample size ca lculations\n\nSOURCE: Evaluation Treatment Outcomes of Anterior Open Bite Treated with Maxillary Intrusive Force by Temporary Anchorage Devices..pdf"
        ],
        "4":[
            "4 \n Aim of the study  \n \nThe present study will be performed to: \n              Evaluate the treatment outcome of anterior open bite by temporary \nanchorage device TADs ( buccal and palatal miniscrows ).\n\nSOURCE: Evaluation Treatment Outcomes of Anterior Open Bite Treated with Maxillary Intrusive Force by Temporary Anchorage Devices..pdf",
            "3 \n  \n               The conventional orthodontic treatments for the correction of an anterior \nopen bite include bite blocks ,high-pull headgear, and new facemask designs . to \nachieve dentoalveolar intrusion of the maxillary posterior segments. Fixed \nmechanics, multiloop edgewise archwires, extraction therapy, intermaxillary \nvertical elastics, and inhibition of molar eruption during growth have also been \nused to treat the anterior open bite. (8-10). \n \n                These modalities have been recommended for intrusion of the maxillary \nposterior segment and anterior dentoalveolar extrusion. However, none of these \ntreatment approaches are satisfactory because of negative effects on the skeletal \nand\/or esthetic pattern and a serious tendency for relapse (11). \n             \n                Recently, dental implants, miniplates, and miniscrews have been used as \nanchorage units in orthodontic  treatments . These techniques can supply  the \nanchorage that is needed for specific dental movements, regardless of patient \ncooperation.\n\nSOURCE: Evaluation Treatment Outcomes of Anterior Open Bite Treated with Maxillary Intrusive Force by Temporary Anchorage Devices..pdf",
            "These techniques can supply  the \nanchorage that is needed for specific dental movements, regardless of patient \ncooperation.  Changes in dentofacial structures resulting from molar and buccal \nsegment intrusion with miniplates placed in the zygoma have been shown in many \nstudies and case reports, and successful molar intrusion and open bite treatments \nhave been reported with miniscrew s anchorage(12-13). \n \n                   In this study for management of anterior open bite , temporary \nanchorage devices (TADs) will be use to intrude the maxillary posterior teeth to \nallow auto  rotation of the mandible to close an anterior open bite\n\nSOURCE: Evaluation Treatment Outcomes of Anterior Open Bite Treated with Maxillary Intrusive Force by Temporary Anchorage Devices..pdf"
        ],
        "5":[
            "Most of the CMT ne uropathies are demyelinating, especially CMT1A which comprises 60  to 65% of \ncases.  \n \nCMT4J is a rare autosomal recessive, peripheral motor demyelinating neuropathy caused by biallelic \npathogenic variants in the FIG4 gene. CMT4J is characterized by childhood  onset gait abnormalities \nand balance difficulties, that rapidly progress to muscle weakness and muscle atrophy during the teen \nor adult years. Onset can be acute or sub -acute, mimicking an acquired neuropathy and often \nmisdiagnosed as chronic inflammatory  demyelinating polyneuropathy (CIDP), or a subacute \npresentation of Guillain -Barre Syndrome. Involvement can be asymmetric and can affect distal as well \nas proximal musculature. Although sensory symptoms are minimal, examination may reveal decreased \nrespon se to touch, pin prick, or vibration distally. Bulbar and cranial nerve functions are often spared; \nintellect is often normal.\n\nSOURCE: A Prospective Natural History and Outcome Measure Discovery Study of Charcot-Marie-Tooth Disease, Type 4J.pdf",
            "Bulbar and cranial nerve functions are often spared; \nintellect is often normal.  \n \nThis study is designed to investigate the clinical characteristics and natural history of CMT4J. We aim \nto follow subjects with a molecularly confirmed diagnosis of CMT4J longitudinally to collect \nstandardized clinical data to evaluate epidemiological characteristics, clinical course, and to identify \npotential outcome measures which may be used in future clinical trials. Clinical d ata collection will \ninclude medical history and physical exam, hematology and biochemical analyses, calf muscle imaging, \nnerve conduction studies, pulmonary function testing and neuropsychological assessments.  \n \nThe study will be conducted in accordance wit h the protocol, Good Clinical Practice (GCP), and the \napplicable regulatory requirements.  \n \n1.2 Background and Rationale  \n \nThere is no causative treatment available for CMT, but therapeutic clinical trials for the most common \ntypes of CMT, like CMT1A, are ongoin g. Most recently, animal models have demonstrated the \npossibility of treating some types of CMT, like CMT4J, with gene transfer therapy through viral \nvectors.\n\nSOURCE: A Prospective Natural History and Outcome Measure Discovery Study of Charcot-Marie-Tooth Disease, Type 4J.pdf",
            "CMT4J diagnosis will be made by both \nclinical manifestations and a confirmed genetic confirmation. Examples of clinical manifestations \nconsistent with CMT4J, include but are not limited to, childho od onset gait abnormalities, poor balance, \nand accelerated, most commonly asymmetric, limb weakness and muscle atrophy, involving distal and \nproximal musculature.  \n \n2.2 Subject Inclusion Criteria  \n \nInclusion Criteria:  \n1. Male or female, all ages  \n2. A molecularly -confi rmed diagnosis of CMT4J  (confirmed by a CLIA certified, CE -marked, \nor equivalent lab): Genomic DNA mutation analysis demonstrating 1) bi -allelic pathogenic \nand\/or likely pathogenic variants (by ACMG criteria) in the FIG4 gene, or 2) bi -allelic \nvariants wit h one pathogenic and\/or likely pathogenic variant in trans with a variant of \nuncertain significance if laboratory evidence and expert consensus exits in support of loss of \nFIG4 function exists.  \n3.\n\nSOURCE: A Prospective Natural History and Outcome Measure Discovery Study of Charcot-Marie-Tooth Disease, Type 4J.pdf"
        ],
        "6":[
            "To be able to understand the condition over time and evaluate these therapies at long term, \nnatur al history studies are indispensable. This study investigates the natural history of CMT4J.  \n \n1.3 Concise Summary of Project  \n \nThis is a multicenter, longitudinal, prospective observational natural history study of subjects with a \nmolecularly confirmed diagnosis of CMT4J. We plan to enroll 20 subjects of any age into a uniform \nprotocol for follow -up and evaluations. We will obtain  demographic and medical history information. \nNatural history data will be collected prospectively on an annual basis and may include \nphysical\/neurological exams, standard laboratory tests, CMT outcome and disability measures, \nneuropsychological tests, ner ve conduction studies (NCS), and imaging studies (muscle MRI). \nPulmonary function test (PFT) and scoliosis series x -ray Subject visits will occur every 12 months\n\nSOURCE: A Prospective Natural History and Outcome Measure Discovery Study of Charcot-Marie-Tooth Disease, Type 4J.pdf",
            "Bulbar and cranial nerve functions are often spared; \nintellect is often normal.  \n \nThis study is designed to investigate the clinical characteristics and natural history of CMT4J. We aim \nto follow subjects with a molecularly confirmed diagnosis of CMT4J longitudinally to collect \nstandardized clinical data to evaluate epidemiological characteristics, clinical course, and to identify \npotential outcome measures which may be used in future clinical trials. Clinical d ata collection will \ninclude medical history and physical exam, hematology and biochemical analyses, calf muscle imaging, \nnerve conduction studies, pulmonary function testing and neuropsychological assessments.  \n \nThe study will be conducted in accordance wit h the protocol, Good Clinical Practice (GCP), and the \napplicable regulatory requirements.  \n \n1.2 Background and Rationale  \n \nThere is no causative treatment available for CMT, but therapeutic clinical trials for the most common \ntypes of CMT, like CMT1A, are ongoin g. Most recently, animal models have demonstrated the \npossibility of treating some types of CMT, like CMT4J, with gene transfer therapy through viral \nvectors.\n\nSOURCE: A Prospective Natural History and Outcome Measure Discovery Study of Charcot-Marie-Tooth Disease, Type 4J.pdf",
            "OBJECTIVES  \n \n1.4 Study Objectives  \n\u2022 To gain a b etter und erstanding of the CMT4J disease course and phen otypic \nspectrum.  \n\u2022 To explore CMT4J g enotype -phen otype correlations t o allow f or better prediction of \ndisease pro gression ba sed on gen etic inf ormation. \n\u2022 To evaluate candidate clinical trial o utcome measures related to motor function, \nquality of life, radiology , and electrophysiology.  To expedite rese arch a nd acces s to \nnew therapi es for rare conditions like CMT4J . \n2 STUDY E LIGIBILITY , ENROLLMENT AND CONSENTING  \n \n2.1 Target and Study Population  \nSubjects with a prior diagnosis of CMT4J will be included. CMT4J diagnosis will be made by both \nclinical manifestations and a confirmed genetic confirmation.\n\nSOURCE: A Prospective Natural History and Outcome Measure Discovery Study of Charcot-Marie-Tooth Disease, Type 4J.pdf"
        ],
        "7":[
            "To be able to understand the condition over time and evaluate these therapies at long term, \nnatur al history studies are indispensable. This study investigates the natural history of CMT4J.  \n \n1.3 Concise Summary of Project  \n \nThis is a multicenter, longitudinal, prospective observational natural history study of subjects with a \nmolecularly confirmed diagnosis of CMT4J. We plan to enroll 20 subjects of any age into a uniform \nprotocol for follow -up and evaluations. We will obtain  demographic and medical history information. \nNatural history data will be collected prospectively on an annual basis and may include \nphysical\/neurological exams, standard laboratory tests, CMT outcome and disability measures, \nneuropsychological tests, ner ve conduction studies (NCS), and imaging studies (muscle MRI). \nPulmonary function test (PFT) and scoliosis series x -ray Subject visits will occur every 12 months\n\nSOURCE: A Prospective Natural History and Outcome Measure Discovery Study of Charcot-Marie-Tooth Disease, Type 4J.pdf",
            "Investigational Site  4 US sites \n\u2022 University of Texas Southwestern Medical Center \/Children\u2019s Health  \n\u2022 University of Iowa  \n\u2022 NIH (National Institute of Neurological Disorders and Stroke)  \n\u2022 Stanford School of Medicine  \nStudy Objectives  \n \n \u2022 To gain a b etter und erstanding of the cours e of illness  \n\u2022 To collect d ata abo ut genotype -phen otype correlations t o allow f or better \nprediction of disease pro gression ba sed on gen etic inf ormation \n\u2022 To investigat e and follow at long t erm differe nt outcome meas ureme nts \n(e.g., m otor, quality of life, radiologic and electrop hysiological)  \n\u2022 To expedite rese arch a nd acces s to new therapi es for rare conditions like \nCMT4J  \nStudy Design  A multicenter, longitudinal, prospective observational natural history study of \nsubjects with a molecular confirmed diagnosis of CMT4J  \nEligibility Criteria  Inclusion Criteria:  \n1. Male or female , all ages  \n2.\n\nSOURCE: A Prospective Natural History and Outcome Measure Discovery Study of Charcot-Marie-Tooth Disease, Type 4J.pdf",
            "Natural History Study CMT4J                                                                                                       Protocol  Number: TBD  \n___________________________________ ________ _____ ____ _______ ___________ __________   \n \n_________________________________ ____________________________________________ ____  \nVersion: 1   Confidential                                      Page 10 of 28 \nDate: 1 August 2023  \n + 4 weeks for up to 2 years. Subjects wh o termin ate from the study prior t o Visit 3 will under go an early \ntermination\/en d of study visit (EO S) if possible. The e arly termination\/end of stud y visit is comprised \nof the Visit 3 asses sments. If needed, the Inve stigator may conduct unschedul ed visits wit h Sponsor\u2019 s \napproval. N o investigational produ ct will be used during th e study. \n \nSince CMT4J is a rare disease, there is a high likelihood that both national and international families \nmay be interested in study participation.  \n \n \nOBJECTIVES  \n \n1.4 Study Objectives  \n\u2022 To gain a b etter und erstanding of the CMT4J disease course and phen otypic \nspectrum.\n\nSOURCE: A Prospective Natural History and Outcome Measure Discovery Study of Charcot-Marie-Tooth Disease, Type 4J.pdf"
        ],
        "8":[
            "To be able to understand the condition over time and evaluate these therapies at long term, \nnatur al history studies are indispensable. This study investigates the natural history of CMT4J.  \n \n1.3 Concise Summary of Project  \n \nThis is a multicenter, longitudinal, prospective observational natural history study of subjects with a \nmolecularly confirmed diagnosis of CMT4J. We plan to enroll 20 subjects of any age into a uniform \nprotocol for follow -up and evaluations. We will obtain  demographic and medical history information. \nNatural history data will be collected prospectively on an annual basis and may include \nphysical\/neurological exams, standard laboratory tests, CMT outcome and disability measures, \nneuropsychological tests, ner ve conduction studies (NCS), and imaging studies (muscle MRI). \nPulmonary function test (PFT) and scoliosis series x -ray Subject visits will occur every 12 months\n\nSOURCE: A Prospective Natural History and Outcome Measure Discovery Study of Charcot-Marie-Tooth Disease, Type 4J.pdf",
            "Investigational Site  4 US sites \n\u2022 University of Texas Southwestern Medical Center \/Children\u2019s Health  \n\u2022 University of Iowa  \n\u2022 NIH (National Institute of Neurological Disorders and Stroke)  \n\u2022 Stanford School of Medicine  \nStudy Objectives  \n \n \u2022 To gain a b etter und erstanding of the cours e of illness  \n\u2022 To collect d ata abo ut genotype -phen otype correlations t o allow f or better \nprediction of disease pro gression ba sed on gen etic inf ormation \n\u2022 To investigat e and follow at long t erm differe nt outcome meas ureme nts \n(e.g., m otor, quality of life, radiologic and electrop hysiological)  \n\u2022 To expedite rese arch a nd acces s to new therapi es for rare conditions like \nCMT4J  \nStudy Design  A multicenter, longitudinal, prospective observational natural history study of \nsubjects with a molecular confirmed diagnosis of CMT4J  \nEligibility Criteria  Inclusion Criteria:  \n1. Male or female , all ages  \n2.\n\nSOURCE: A Prospective Natural History and Outcome Measure Discovery Study of Charcot-Marie-Tooth Disease, Type 4J.pdf",
            "OBJECTIVES  \n \n1.4 Study Objectives  \n\u2022 To gain a b etter und erstanding of the CMT4J disease course and phen otypic \nspectrum.  \n\u2022 To explore CMT4J g enotype -phen otype correlations t o allow f or better prediction of \ndisease pro gression ba sed on gen etic inf ormation. \n\u2022 To evaluate candidate clinical trial o utcome measures related to motor function, \nquality of life, radiology , and electrophysiology.  To expedite rese arch a nd acces s to \nnew therapi es for rare conditions like CMT4J . \n2 STUDY E LIGIBILITY , ENROLLMENT AND CONSENTING  \n \n2.1 Target and Study Population  \nSubjects with a prior diagnosis of CMT4J will be included. CMT4J diagnosis will be made by both \nclinical manifestations and a confirmed genetic confirmation.\n\nSOURCE: A Prospective Natural History and Outcome Measure Discovery Study of Charcot-Marie-Tooth Disease, Type 4J.pdf"
        ],
        "9":[
            "77. Nestle, F. O., S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, G. Burg, and D. Schadendorf. 1998. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Med. 4(3):328. 78. Schuler-Thurner B., Dieckmann D., Keikavoussi P., Bender A., Maczek Ch., Jonuleit H., R\u00f6der C., Haendle I., Leisgang W., Dunbar R., Cerundolo V., Driesch P., Knop J., Br\u00f6cker E., Enk A., K\u00e4mpgen E., Schuler G. 2000. Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells. J immunol 165:3492.\n\nSOURCE: PHASE II STUDY OF IMMUNIZATION WITH DENDRITIC CELLS AND LOW DOSE OF INTERLEUKIN-2, IN PATIENTS WITH ADVANCED MELANOMA.pdf",
            "Hum Gene Ther. 6:87. 75. Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, M. E. Dudley, S. L. Schwarz, P. J. Spiess, J. R. Wunderlich, M. P. Parkhurst, Y. Kawakami, C. A. Seipp, J. H. Einhorn, and D. E. White. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med. 4(3):321. 76. Baar J. 1999. Clinical applications of dendritic cell cancer vaccines. Oncologist. 4:140.\n\nSOURCE: PHASE II STUDY OF IMMUNIZATION WITH DENDRITIC CELLS AND LOW DOSE OF INTERLEUKIN-2, IN PATIENTS WITH ADVANCED MELANOMA.pdf",
            "1994. Identification of the immunodominant peptides of the Mart-1 human melanoma antigen recognized by the majority of HLA-A2 restricted tumor infiltrating lymphocytes. J. Exp. Med.. 180:347. 27. Kawakami, Y., S. Eliyahu, C. Jennings, K. Sakaguchi, X. Kang, S. Southwood, P. Robbins, A. Sette, E. Appella, and S. A. Rosenberg. 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol. 154:3961. 28. Brichard, V., A. Van Pel, T. Wolfel, C. Wolfel, E. De Plaen, B. Leth\u00e8, P. Coulie, and T. Boon. 1993.\n\nSOURCE: PHASE II STUDY OF IMMUNIZATION WITH DENDRITIC CELLS AND LOW DOSE OF INTERLEUKIN-2, IN PATIENTS WITH ADVANCED MELANOMA.pdf"
        ],
        "10":[
            "Electronic Stimulation for Muscle Toning and Circumferential Reduction  Version 2.0  \n \n       Page 22 of 35 \n or application (including supplementary application), or any other unanticipated serious problem \nassociated with a device that relates to the rights, safety, or welfare of subjects.\u201d  \n \n7.2 CLASSIFICATION OF AN EVENT  \n7.2.1  Severity of Event  \nEach adverse event should be assessed for its severity, or the intensity of an event experienced by the \nsubject, using the following classifications:  \n1 = Mild  Discomfort noticed, but no disruption to daily activity  \n2 = Moderate  Discomfort sufficient to reduce or affect normal daily activity  \n3 = Severe  Inability to work or perform normal daily activity  \n \n7.2.2  Relationship to the Investigational Device  \nThe investigator should assess the relationship of the adverse event to the investigational device. The \nrelationship should be assessed using the categories presented in Table 2.\n\nSOURCE: Prospective Clinical Evaluation of the Safety and Efficacy of NON-INVASIVE Electronic Stimulation for Improvement of Muscle Strengt.pdf",
            "The heterogeneity of antigenic expression in tumors must also be considered, so vaccination with tumor extracts guarantees immunization with multiple antigens. Another difficulty to be considered is the ability of tumors to evade immune system recognition (83). These escape strategies range from inhibiting antigen presentation to producing immunosuppressive substances such as TGF-beta and IL-10 (84). The relative importance of these potential mechanisms in reducing the potential of vaccine-based immunotherapy has yet to be established. Nevertheless, it is crucial to investigate these obstacles and develop appropriate clinical protocols that harness the full potential of cellular vaccine-based immunotherapy, which has been convincingly demonstrated in murine models. Therefore, we have decided to present a second study to the respective committee, building on the experience gained and the recently obtained funding from FONDEF, to develop an optimized protocol that alternates dendritic cell vaccines with the use of low doses of IL-\n\nSOURCE: PHASE II STUDY OF IMMUNIZATION WITH DENDRITIC CELLS AND LOW DOSE OF INTERLEUKIN-2, IN PATIENTS WITH ADVANCED MELANOMA.pdf",
            "Electronic Stimulation for Muscle Toning and Circumferential Reduction  Version 2.0  \n \n       Page 32 of 35 \n emergency, such protocol deviations must be reported to the Sponsor and the reviewing IRB as soon as \npossible, but no later than five working days after the emergency occurred.  \nIn the event of a significant deviation from the protocol due to an accident or mistake, the investigator \nor designee must contact the Sponsor at the earliest possible time by telephone to discuss the deviation \nand its impact on the study and subject conti nuation in the study. These discussions will be documented \nby the investigator and the Sponsor and reviewed by the monitor.  \n \n12.5  PUBLICATION AND DATA SHARING POLICY  \nThe data produced by this Lutronic\u2010sponsored study is the sole property of Lutronic.  Thereby, \nabstracts, publications and presentations of this data must be pre\u2010approved by Lutronic in writing (e\u2010\nmail approval is acceptable).  The Sponsor must also be provided with the opportunity  to review all \ninvestigator\u2010prepared abstracts, publications or presentations.\n\nSOURCE: Prospective Clinical Evaluation of the Safety and Efficacy of NON-INVASIVE Electronic Stimulation for Improvement of Muscle Strengt.pdf"
        ],
        "11":[
            "have been combined with subsequent immunotherapy based on dendritic cells pulsed with anti-idiotypic antigens. The results in treating minimal residual disease have been more than satisfactory, with 8 out of 11 treated patients eliminating residual malignant cells after vaccination (80).  Vaccination of Melanoma Patients Using DCs Loaded with Allogeneic Melanoma Extracts In Chile, we have completed the first phase I clinical trial for treating advanced malignant melanoma using dendritic cell vaccines loaded with allogeneic tumor extracts. Since chemotherapy and radiotherapy only offer palliative effects in advanced melanoma, resulting in an inferior prognosis for these patients, we intended to develop a protocol that would adapt to the reality of our country, allowing for a combination of high technology and low costs. In summary, the results obtained in the Phase I clinical trial, which were published in (Escobar et al. Clin. Exp. Immunol.\n\nSOURCE: PHASE II STUDY OF IMMUNIZATION WITH DENDRITIC CELLS AND LOW DOSE OF INTERLEUKIN-2, IN PATIENTS WITH ADVANCED MELANOMA.pdf",
            "Hum Gene Ther. 6:87. 75. Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, M. E. Dudley, S. L. Schwarz, P. J. Spiess, J. R. Wunderlich, M. P. Parkhurst, Y. Kawakami, C. A. Seipp, J. H. Einhorn, and D. E. White. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med. 4(3):321. 76. Baar J. 1999. Clinical applications of dendritic cell cancer vaccines. Oncologist. 4:140.\n\nSOURCE: PHASE II STUDY OF IMMUNIZATION WITH DENDRITIC CELLS AND LOW DOSE OF INTERLEUKIN-2, IN PATIENTS WITH ADVANCED MELANOMA.pdf",
            "77. Nestle, F. O., S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, G. Burg, and D. Schadendorf. 1998. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Med. 4(3):328. 78. Schuler-Thurner B., Dieckmann D., Keikavoussi P., Bender A., Maczek Ch., Jonuleit H., R\u00f6der C., Haendle I., Leisgang W., Dunbar R., Cerundolo V., Driesch P., Knop J., Br\u00f6cker E., Enk A., K\u00e4mpgen E., Schuler G. 2000. Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells. J immunol 165:3492.\n\nSOURCE: PHASE II STUDY OF IMMUNIZATION WITH DENDRITIC CELLS AND LOW DOSE OF INTERLEUKIN-2, IN PATIENTS WITH ADVANCED MELANOMA.pdf"
        ],
        "12":[
            "An average of the % of the correctly \nidentified post treatment  photographs chosen by Blinded Reviewer will be calculated and used to \ndetermine  \n \nBar, pie charts or graphs indicating percentages of the correctly identified post treatment photographs  \nchosen by Blinded Reviewer may also be used to analyses  efficacy.  \n \nThe % of the correctly identified post treatment photographs chosen by Blinded Reviewer of all subjects  \nwho received all treatment s with the investigational device and for whom all valid post -baseline  \nassessment was obtained will be analyzed  for these primary endpoints. Multiple imputation method or  \nmodelling of available data may be used for missing data as appropriate.  \n \n9.8 ANALYSIS OF SECONDARY ENDPOINTS  \nFor the analysis of changes in muscle tone and muscle strength , circumference of the extremities and \nsubjects\u2019 assessment of satisfaction with the treatment secondary endpoints, the following analysis will \nbe considered:  \n \nSummary tables of changes in measurements  of muscle tone and strength , circumference and subjects\u2019 \nassessment of satisfaction at 1 and 3 months  post last treatment as compared to baseline will be \ndisplayed as mean difference, standard deviation and standard error.\n\nSOURCE: Prospective Clinical Evaluation of the Safety and Efficacy of NON-INVASIVE Electronic Stimulation for Improvement of Muscle Strengt.pdf",
            "Electronic Stimulation for Muscle Toning and Circumferential Reduction  Version 2.0  \n \n       Page 22 of 35 \n or application (including supplementary application), or any other unanticipated serious problem \nassociated with a device that relates to the rights, safety, or welfare of subjects.\u201d  \n \n7.2 CLASSIFICATION OF AN EVENT  \n7.2.1  Severity of Event  \nEach adverse event should be assessed for its severity, or the intensity of an event experienced by the \nsubject, using the following classifications:  \n1 = Mild  Discomfort noticed, but no disruption to daily activity  \n2 = Moderate  Discomfort sufficient to reduce or affect normal daily activity  \n3 = Severe  Inability to work or perform normal daily activity  \n \n7.2.2  Relationship to the Investigational Device  \nThe investigator should assess the relationship of the adverse event to the investigational device. The \nrelationship should be assessed using the categories presented in Table 2.\n\nSOURCE: Prospective Clinical Evaluation of the Safety and Efficacy of NON-INVASIVE Electronic Stimulation for Improvement of Muscle Strengt.pdf",
            "Electronic Stimulation for Strength and Muscle Toning   Version 2.0 \n \nProtocol Number: AFL19006         Page 7 of 35 \n 11. Subjects unwilling or unable to adhere to all study requirements for treatment and \nfollow -up. \n12. Investigator may exclude any subject at any time at his\/her discretion . \n \nPrimary Endpoint:  \nPhotographic evaluation by an independent, blinded reviewer with correct identification of pre -\ntreatment baseline images when compared to post -treatment i mages taken at follow up visits.  \n \nSecondary Endpoints:   \n1. Global Aesthetic Improvement grading by Expert Clinician.  \n2. Improvement of muscle strength as measured by a dynamometer at follow up visits \ncompared to baseline measurements.  \n3. Reduction in  core  circumference as measured by Seca Circumferential System at follow \nup visits compared to baseline measurement.  \n4. To assess subject satisfaction using Satisfaction Survey at each follow up visit.  \n \nSafety Endpoints:  Subject\u2019s assessment of discomfort as measured by a 0 -10 numeric rating scale.  \nSubjects experiencing a treatment -related adverse event (AE).\n\nSOURCE: Prospective Clinical Evaluation of the Safety and Efficacy of NON-INVASIVE Electronic Stimulation for Improvement of Muscle Strengt.pdf"
        ],
        "13":[
            "Electronic Stimulation for Strength and Muscle Toning   Version 2.0 \n \nProtocol Number: AFL19006         Page 6 of 35 \n Protocol Synopsis  \nProtocol Number:  AFL19006  \nProtocol Title:  Prospective Clinical Evaluation of the Safety and Efficacy of NON -INVASIVE Electronic Stimulation \nfor Improvement of Muscle Strength and Toning, Circumferential Reduction of the Core and \nExtremities  \nInvestigational Devices:  The Accufit Electrical Muscle Stimulation device is an FDA cleared two-channel muscle \nstimulator that provides up to 8 electrodes with unique waveforms for muscle stimulation.  \nDevelopment Phase:  Evaluation  \nStudy Objective:  The objective of this clinical study is to assess the safety and efficacy of a novel electrical \nstimulation device for use in improving muscle strength  and toning  of the core and extremities .\n\nSOURCE: Prospective Clinical Evaluation of the Safety and Efficacy of NON-INVASIVE Electronic Stimulation for Improvement of Muscle Strengt.pdf",
            "2.3 POTENTIAL RISKS AND BENEFITS  \n2.3.1 Known Potential Risks  \nExpected adverse events of the muscle Electrical stimulation treatment procedure include : \n\u2022 Transient tenderness  \n\u2022 Erythema  \n\u2022 Edema  \n\u2022 Discomfort  \nOther adverse events may include and include :  \n\u2022 Localized tenderness  \n\u2022 Skin burn   \n\u2022 Hyperpigmentation  \n\u2022 Hypopigmentation  \n\u2022 Blister  \n\u2022 Changes in skin laxity  (rarely, skin contour irregularities, dimpling, and asymmetry ).    \n \nRisks will be mitigated by conducting this protocol with an investigator experienced in the therapeutic \narea of the clinical investigation.  The investigator will be trained by the sponsor on the use of the \ndevice.  The device design incorporates safety mechanisms which minimize risks.  Patients will also be \nrigorously screened prior to their enr ollment and rigorously followed over the course of the study.  \n \n2.3.2 Contraindications  \nDo not use this device on the pectoral area or patients who have a cardiac pacemaker, implanted \ndefibrillator or other implanted metallic or electronic device.\n\nSOURCE: Prospective Clinical Evaluation of the Safety and Efficacy of NON-INVASIVE Electronic Stimulation for Improvement of Muscle Strengt.pdf",
            "Electrical Muscle \nStimulation is known to assist in muscle contraction.  \n \n2.1.1  Device Name and Indications for Use  \nMagnet -based and Direct muscle stimulation devices are commonly used to generate current flow \nthrough the muscles in order to activate the muscle.   The Accufit Electrical Muscle Stimulation device is \nan FDA cleared device having a two -channel stimulator that provides up to 8 electrodes with waveforms \nof interferential and biphasic for muscle stimulation.  The Accufit system  is indicated for relaxation of \nmuscles, muscle re -education, reduction of pain and increased local blood circulation.  \n \n2.1.2 Mechanism of Actions  \nMuscle stimulation technology has been around for many decades and has been shown to be safe and \neffective for a variety of clinical applications. The foundational basis for the technology revolves around \nelectrical current flowing through the muscle can be used to activate the muscle.\n\nSOURCE: Prospective Clinical Evaluation of the Safety and Efficacy of NON-INVASIVE Electronic Stimulation for Improvement of Muscle Strengt.pdf"
        ],
        "14":[
            "2.3 POTENTIAL RISKS AND BENEFITS  \n2.3.1 Known Potential Risks  \nExpected adverse events of the muscle Electrical stimulation treatment procedure include : \n\u2022 Transient tenderness  \n\u2022 Erythema  \n\u2022 Edema  \n\u2022 Discomfort  \nOther adverse events may include and include :  \n\u2022 Localized tenderness  \n\u2022 Skin burn   \n\u2022 Hyperpigmentation  \n\u2022 Hypopigmentation  \n\u2022 Blister  \n\u2022 Changes in skin laxity  (rarely, skin contour irregularities, dimpling, and asymmetry ).    \n \nRisks will be mitigated by conducting this protocol with an investigator experienced in the therapeutic \narea of the clinical investigation.  The investigator will be trained by the sponsor on the use of the \ndevice.  The device design incorporates safety mechanisms which minimize risks.  Patients will also be \nrigorously screened prior to their enr ollment and rigorously followed over the course of the study.  \n \n2.3.2 Contraindications  \nDo not use this device on the pectoral area or patients who have a cardiac pacemaker, implanted \ndefibrillator or other implanted metallic or electronic device.\n\nSOURCE: Prospective Clinical Evaluation of the Safety and Efficacy of NON-INVASIVE Electronic Stimulation for Improvement of Muscle Strengt.pdf",
            "NCS : Electrical stimulation may cause muscle con traction that may be uncomfortable. Also, there may \nbe mild muscle soreness after muscle testing. This may last for one to two days. Subjects may \nexperience some slight discomfort from having to lay or sit still during the  procedure.  \n \nMRI : Subjects are at  risk for injury from the MRI magnet if they have pacemakers or other implanted \nelectrical devices, brain stimulators, some types of dental implants, aneurysm clips, metallic prostheses, \npermanent eyeliners, implanted delivery pump, or shrapnel fragments. Welders and metal workers are \nalso at risk for injury because of possible small metal fragments in the eye of which they may be \nunaware. Individuals will be screened for these conditions and implants before having any scan, and if \nthey have any, they will not receive an MRI scan (or per the clinical judgement of a certified radiologist \nand radiology staff, may have a modified MRI that is deemed safe). In addition, all magnetic objects \nmust be removed before entering the MRI scan room.\n\nSOURCE: A Prospective Natural History and Outcome Measure Discovery Study of Charcot-Marie-Tooth Disease, Type 4J.pdf",
            "Electronic Stimulation for Muscle Toning and Circumferential Reduction  Version 2.0  \n \n       Page 20 of 35 \n Pain Scale Rating    x x x x x x x   \nAdverse Events   x x x x x x x x x x \n \n6.5.6 Safety Assessments  \nAssess for adverse events immediately post -treatments and at the follow -up visits.  \n \n6.5.7 Unscheduled Visit  \nAny unscheduled visit or examine should be documented in the subject\u2019s medical record and adverse \nevent form (if applicable) stating the reason for the visit and any actions taken. The Sponsor should be \nnotified of the unscheduled visit.  \n6.6 STUDY TREATMENT  \nThis study involves up to 8  treatments to be conducted after obtaining informed consent, screening for \ninclusion\/exclusion, complying with standardized photography requirements, and completing pregnancy \ntests, if applicable.  \n \n6.6.1  Subject Preparation for Study Treatment  \nThe investigator, sub -investigator, or delegated clinician will first identify the skin areas to which \ntreatment\/exposure is to be performed.\n\nSOURCE: Prospective Clinical Evaluation of the Safety and Efficacy of NON-INVASIVE Electronic Stimulation for Improvement of Muscle Strengt.pdf"
        ],
        "15":[
            "2.3 POTENTIAL RISKS AND BENEFITS  \n2.3.1 Known Potential Risks  \nExpected adverse events of the muscle Electrical stimulation treatment procedure include : \n\u2022 Transient tenderness  \n\u2022 Erythema  \n\u2022 Edema  \n\u2022 Discomfort  \nOther adverse events may include and include :  \n\u2022 Localized tenderness  \n\u2022 Skin burn   \n\u2022 Hyperpigmentation  \n\u2022 Hypopigmentation  \n\u2022 Blister  \n\u2022 Changes in skin laxity  (rarely, skin contour irregularities, dimpling, and asymmetry ).    \n \nRisks will be mitigated by conducting this protocol with an investigator experienced in the therapeutic \narea of the clinical investigation.  The investigator will be trained by the sponsor on the use of the \ndevice.  The device design incorporates safety mechanisms which minimize risks.  Patients will also be \nrigorously screened prior to their enr ollment and rigorously followed over the course of the study.  \n \n2.3.2 Contraindications  \nDo not use this device on the pectoral area or patients who have a cardiac pacemaker, implanted \ndefibrillator or other implanted metallic or electronic device.\n\nSOURCE: Prospective Clinical Evaluation of the Safety and Efficacy of NON-INVASIVE Electronic Stimulation for Improvement of Muscle Strengt.pdf",
            "NCS : Electrical stimulation may cause muscle con traction that may be uncomfortable. Also, there may \nbe mild muscle soreness after muscle testing. This may last for one to two days. Subjects may \nexperience some slight discomfort from having to lay or sit still during the  procedure.  \n \nMRI : Subjects are at  risk for injury from the MRI magnet if they have pacemakers or other implanted \nelectrical devices, brain stimulators, some types of dental implants, aneurysm clips, metallic prostheses, \npermanent eyeliners, implanted delivery pump, or shrapnel fragments. Welders and metal workers are \nalso at risk for injury because of possible small metal fragments in the eye of which they may be \nunaware. Individuals will be screened for these conditions and implants before having any scan, and if \nthey have any, they will not receive an MRI scan (or per the clinical judgement of a certified radiologist \nand radiology staff, may have a modified MRI that is deemed safe). In addition, all magnetic objects \nmust be removed before entering the MRI scan room.\n\nSOURCE: A Prospective Natural History and Outcome Measure Discovery Study of Charcot-Marie-Tooth Disease, Type 4J.pdf",
            "Electronic Stimulation for Strength and Muscle Toning   Version 2.0 \n \nProtocol Number: AFL19006         Page 6 of 35 \n Protocol Synopsis  \nProtocol Number:  AFL19006  \nProtocol Title:  Prospective Clinical Evaluation of the Safety and Efficacy of NON -INVASIVE Electronic Stimulation \nfor Improvement of Muscle Strength and Toning, Circumferential Reduction of the Core and \nExtremities  \nInvestigational Devices:  The Accufit Electrical Muscle Stimulation device is an FDA cleared two-channel muscle \nstimulator that provides up to 8 electrodes with unique waveforms for muscle stimulation.  \nDevelopment Phase:  Evaluation  \nStudy Objective:  The objective of this clinical study is to assess the safety and efficacy of a novel electrical \nstimulation device for use in improving muscle strength  and toning  of the core and extremities .\n\nSOURCE: Prospective Clinical Evaluation of the Safety and Efficacy of NON-INVASIVE Electronic Stimulation for Improvement of Muscle Strengt.pdf"
        ],
        "16":[
            "POSTPRANDIAL  AMBULATION  IN GESTATIONAL  DIABETES  | Version  3: 9.19.202 2  \n \nallocated  to. They  will then receive  counseling  specific  to their group.  They  will be provided  \nwith an activity  monitor  and instructed  on how to use as well as charg e and upload  data.  They  \nwill be provided  with the information  from  the manufacturer  as well as trouble  shooting  \nguide.  \no As is the standard  of care in this clinic,  both groups  would  be equipped  with glucometers  and \ndiabetic  testing  supplies.  Both  groups  woul d receive  the same  diabetes  and nutrition  \ncounseling  from  qualified  nursing  staff.  Additionally,  all participants  will be provided  with \nBluetooth  enabled  pedometers.\n\nSOURCE: The effect of postprandial ambulation on birth weight percentile in patients with gestational diabetes mellitus.pdf",
            "At Women  and Infants  Hospital  in the Division  of \nMaternal  Fetal  Medicine  we care for a large  volume  of patients  with gestational  diabetes  and are well \npoised  to assess  how a simple  intervention  such as postprandial  ambulation  can impact  maternal  and \nneonatal  outcomes.   \n \nHypothesis:  We hypo thesize  that postprandial  ambulation  in patients  with gestational  diabetes  will be \nassociated  with a decrease  in neonatal  birth  percentile  as compared  to patients  who do not ambulate  \npostprandially.    \n \n2.\n\nSOURCE: The effect of postprandial ambulation on birth weight percentile in patients with gestational diabetes mellitus.pdf",
            "Background\/Introduction:  \nGestational  Diabetes  Mellitus  (GDM)  affects 6-8% of pregnancies  in the United  States (1). Patients  who \nare diagnosed  with GDM  are unable  to maintain  euglycemia  due to insulin  resistance,  particularly  \npostprandially (2). This postprandial  hyperglycemia  has been  tied to numerous  clinical  outcomes  including  \nincreased  risk for hypertensive  disorders,  cesarean  delivery,  shoulder  dystocia,  increased  birth weight  and \nlarge  for gestational  age (LGA)  neonates (2). The initial  treatment  of GDM  includes  lifestyle  changes  \nincluding  daily  exercise  and adoption  of the American  Diabetes  Association  (ADA)  diet(3). Exercise  has \nbeen  shown  to improve  glucose  levels  in patients  with gestational  diabetes (4, 5). However  an optimal  \nexercise  regimen  has yet to be established.\n\nSOURCE: The effect of postprandial ambulation on birth weight percentile in patients with gestational diabetes mellitus.pdf"
        ],
        "17":[
            "POSTPRANDIAL  AMBULATION  IN GESTATIONAL  DIABETES  | Version  3: 9.19.202 2  \n \nallocated  to. They  will then receive  counseling  specific  to their group.  They  will be provided  \nwith an activity  monitor  and instructed  on how to use as well as charg e and upload  data.  They  \nwill be provided  with the information  from  the manufacturer  as well as trouble  shooting  \nguide.  \no As is the standard  of care in this clinic,  both groups  would  be equipped  with glucometers  and \ndiabetic  testing  supplies.  Both  groups  woul d receive  the same  diabetes  and nutrition  \ncounseling  from  qualified  nursing  staff.  Additionally,  all participants  will be provided  with \nBluetooth  enabled  pedometers.\n\nSOURCE: The effect of postprandial ambulation on birth weight percentile in patients with gestational diabetes mellitus.pdf",
            "2. STUDY  DESIGN,  METHODS,  AND  PROCEDURES  \n \n\u2022 Study  design:   \no This is a randomized  controlled  trial of postprandial  ambulation  to decrease  birthweight  \npercentile  in patients  with GDM  \no Patients  who are diagnosed  with GDM  and enrolled  in the Diabetes  in Pregnancy  Program  in \nthe Division  of Maternal  Fetal  Medicine  at Women  and Infants  Hospital  of Rhode  Island  will \nbe approach  for inclusion  in the study.  After  consent  is obtained,  patients  with GDM  will be \nrandomized  into one of two groups.   \n\u25aa Group  1: intervention  group:  20 minutes  of walking  after meals  \n\u25aa Grou p 2: non-intervention  group:  routine  activity  \no Randomization  will occur  via computer  generated  randomization  in blocks  of 10.\n\nSOURCE: The effect of postprandial ambulation on birth weight percentile in patients with gestational diabetes mellitus.pdf",
            "At Women  and Infants  Hospital  in the Division  of \nMaternal  Fetal  Medicine  we care for a large  volume  of patients  with gestational  diabetes  and are well \npoised  to assess  how a simple  intervention  such as postprandial  ambulation  can impact  maternal  and \nneonatal  outcomes.   \n \nHypothesis:  We hypo thesize  that postprandial  ambulation  in patients  with gestational  diabetes  will be \nassociated  with a decrease  in neonatal  birth  percentile  as compared  to patients  who do not ambulate  \npostprandially.    \n \n2.\n\nSOURCE: The effect of postprandial ambulation on birth weight percentile in patients with gestational diabetes mellitus.pdf"
        ],
        "18":[
            "POSTPRANDIAL  AMBULATION  IN GESTATIONAL  DIABETES  | Version  3: 9.19.202 2  \n \nallocated  to. They  will then receive  counseling  specific  to their group.  They  will be provided  \nwith an activity  monitor  and instructed  on how to use as well as charg e and upload  data.  They  \nwill be provided  with the information  from  the manufacturer  as well as trouble  shooting  \nguide.  \no As is the standard  of care in this clinic,  both groups  would  be equipped  with glucometers  and \ndiabetic  testing  supplies.  Both  groups  woul d receive  the same  diabetes  and nutrition  \ncounseling  from  qualified  nursing  staff.  Additionally,  all participants  will be provided  with \nBluetooth  enabled  pedometers.\n\nSOURCE: The effect of postprandial ambulation on birth weight percentile in patients with gestational diabetes mellitus.pdf",
            "POSTPRANDIAL  AMBULATION  IN GESTATIONAL  DIABETES  | Version  3: 9.19.202 2  \n \nAll participants will be assigned a study ID when they are enrolled. Throughout the study, this ID will be \nused to link their de -identified study data to the study key which will include PHI and identifiable data \nthat are collected on the data form. The remainder of the data which will by associated with the study ID \nwill be collected in REDCap. The study key  will be  kept in a secure file in a passw ord protected folder on \nthe hospital network drive.  The key will be destroyed upon completion of the manuscript.  The coded  data,  \nhowever  will be kept after the completion  of the study  for use in future  research.  \n \n4. Material\/Specimen  Management  \nNo specimens  will be used.   \nParticipants  will be allowed  to keep  their activity  tracker  for personal  use at the end of the study.  \n \n5.\n\nSOURCE: The effect of postprandial ambulation on birth weight percentile in patients with gestational diabetes mellitus.pdf",
            "POSTPRANDIAL  AMBULATION  IN GESTATIONAL  DIABETES  | Version  3: 9.19.202 2  \n \nProject  Title : The effect  of postprandial  ambulation  on birth  weight  percentile  in patients  with gestational  \ndiabetes  mellitus  \n \nPrincip al investigator:  Dr. Anna  Whelan  \nFaculty  sponsor\/Co -PI: Dr. Martha  Kole -White  \n \n1. OBJECTIVES,  SPECIFIC  AIMS,  BACKGROUND,  AND  SIGNIFICANCE  \n \nObjective:  To assess  the effect  of postprandial  ambulation  on birth  weight  in patients  with gestational  \ndiabetes  as compared  to routine  activity.  \n \nBackground\/Introduction:  \nGestational  Diabetes  Mellitus  (GDM)  affects 6-8% of pregnancies  in the United  States (1).\n\nSOURCE: The effect of postprandial ambulation on birth weight percentile in patients with gestational diabetes mellitus.pdf"
        ],
        "19":[
            "We see it as important to interview a range of patients having undergone TURBT, TURP or \nTUEP, at different hospitals in different parts of England. This is so we can gain a broad \nrange of perspectives about different care pathways that have been developed,  and to gain \na broad representation of the patient experience. We will conduct interviews with patients \nwho have had surgery at hospitals with different day -case rates because it is possible that \nfactors relevant in one hospital that performs a certain vol ume of day -case endourology \nsurgery might not be the same in other hospitals.  \nMethods  \nStudy Population  \nPatients who have recently undergone day -case transurethral resection of bladder tumour \n(TURBT), transurethral resection of prostate (TURP), or transurethral enucleation of the \nprostate (TUEP) at an NHS hospital  in England .  \nInclusion criteria  \n\u2022 Adults aged \uf0b318 \n\u2022 Experienced day -case TURBT, TURP or TUEP within the past 6 weeks  \n\u2022 Willing and able to provide informed consent  \n\u2022 English speaking\n\nSOURCE: Understanding the patient experience of day-case bladder tumour resection, and prostate resection or enucleation.pdf",
            "The interviews will be recorded. \nAfter, the research team will listen to the m to find common patient experiences. They will \nlook for ways that future patient\u2019s experiences could be made better.  \nResearch Question  \nWhat is the patient experience of  day-case TURBT, TURP and TUEP ?  \n \nRationale and background  \nResource constraints and evolving patient demographics mean that the waiting lists for \nelective surgery in the NHS are greater than ever. Nationally, the median average \npercentage of patients receiving transurethral resection of bladder tumour (TURBT) \ntreatment within 62 days of referral is only 13.1% (1). For patients requiring surgical \ntreatment for acute urinary retention, the median average national hospital wait time \nexceeds five months  (1).\n\nSOURCE: Understanding the patient experience of day-case bladder tumour resection, and prostate resection or enucleation.pdf",
            "As well as reducing pressure on inpatient service s, \ngreater day -case adoption offers to reduce financial costs, shorten waiting lists by allowing \ngreater access to day -case theatres away from the acute hospital, and reduce \nenvironmental impact by adopting a less resource -intensive approach. It also offer s a more \nstandardised patient experience , however we do not understand a great deal about the \nlived patient experience after discharge .  \n \nNational day -case rates for of TURBT , and bladder outflow obstruction surgery using TURP \nor TUEP,  have increased over the past five years . Many hospitals have well -established \npathways, whilst others are newly adopting this approach, or not yet adopting day -case \nsurgery for these operation types at all. There is an opportunity to understand the patient \nexperience of different day -case surge ry pathways for these operations of interest, so that \nwe might understand factors contributing to a favourable or unfav ourable experience. This \nknowledge could inform future day -case pathway development and modification is a way \nthat is more acceptable for patients.\n\nSOURCE: Understanding the patient experience of day-case bladder tumour resection, and prostate resection or enucleation.pdf"
        ],
        "20":[
            "The Getting It Right First Time (GIRFT) programme is an expert clinician -led a nd data -driven \nnational quality improvement programme aiming to improve standards and decrease \nunwarranted variation in clinical care (6). Separate GIRFT workstreams exist for each \nmedical and surgical specialty. The GIRFT urology programme advocates for increased day -\ncase rates for common endourology operations and recommends a \u201cday -case by default\u201d \napproach to TURBT. The GIRFT programme r ecommend ed day-case adoption in the 2018 \nGIRFT Urology National Report and their GIRFT academy service delivery guides (7)(8)(9). At \nthe intensive deep dive visits that GIRFT perform to every single urology unit in England, \nday-case pathways are commonly discussed as a target  for quality improvement. In the five \nyears since the 2018 report, trends towards increasing day -case rates have been observed, \nhowever there remains significant nationwide variation in the rates of day -case surgery \nperformed for TURBT, and bladder outflow obstruction operations such as TURP  and TUEP.\n\nSOURCE: Understanding the patient experience of day-case bladder tumour resection, and prostate resection or enucleation.pdf",
            "We see it as important to interview a range of patients having undergone TURBT, TURP or \nTUEP, at different hospitals in different parts of England. This is so we can gain a broad \nrange of perspectives about different care pathways that have been developed,  and to gain \na broad representation of the patient experience. We will conduct interviews with patients \nwho have had surgery at hospitals with different day -case rates because it is possible that \nfactors relevant in one hospital that performs a certain vol ume of day -case endourology \nsurgery might not be the same in other hospitals.  \nMethods  \nStudy Population  \nPatients who have recently undergone day -case transurethral resection of bladder tumour \n(TURBT), transurethral resection of prostate (TURP), or transurethral enucleation of the \nprostate (TUEP) at an NHS hospital  in England .  \nInclusion criteria  \n\u2022 Adults aged \uf0b318 \n\u2022 Experienced day -case TURBT, TURP or TUEP within the past 6 weeks  \n\u2022 Willing and able to provide informed consent  \n\u2022 English speaking\n\nSOURCE: Understanding the patient experience of day-case bladder tumour resection, and prostate resection or enucleation.pdf",
            "They can be performed under general or \nspinal anaesthesia.  \n \nFor 12 months from December 2021, the national average day -case rate for transurethral \nresection of bladder tumour In England was 21.1%, and ranged from 0% to 87.3% at \ndifferent hospitals, with an interquartile range (IQR) of 10.5% to 37.7%, and 23,071 cas es \nperformed in total. For bladder outflow obstruction surgery the median day -case rate was \n7.7% (range 0% to 82.4%, IQR 4.4% to 19.1%, 18,912 cases), and this includes TURP and \nTUEP. This demonstrates that for these common operations there is significant variation in \npractice across England.  \n \nThe Getting It Right First Time (GIRFT) Urology programme advocates for a \u201cday -case by \ndefault\u201d approach to TURBT, and that day -case surgery should ideally be offered for \nprostate resection and enucleation.\n\nSOURCE: Understanding the patient experience of day-case bladder tumour resection, and prostate resection or enucleation.pdf"
        ],
        "21":[
            "As well as reducing pressure on inpatient service s, \ngreater day -case adoption offers to reduce financial costs, shorten waiting lists by allowing \ngreater access to day -case theatres away from the acute hospital, and reduce \nenvironmental impact by adopting a less resource -intensive approach. It also offer s a more \nstandardised patient experience , however we do not understand a great deal about the \nlived patient experience after discharge .  \n \nNational day -case rates for of TURBT , and bladder outflow obstruction surgery using TURP \nor TUEP,  have increased over the past five years . Many hospitals have well -established \npathways, whilst others are newly adopting this approach, or not yet adopting day -case \nsurgery for these operation types at all. There is an opportunity to understand the patient \nexperience of different day -case surge ry pathways for these operations of interest, so that \nwe might understand factors contributing to a favourable or unfav ourable experience. This \nknowledge could inform future day -case pathway development and modification is a way \nthat is more acceptable for patients.\n\nSOURCE: Understanding the patient experience of day-case bladder tumour resection, and prostate resection or enucleation.pdf",
            "A fundamental question that remains  largely  unanswered is what the experience is like for \npatients who undergo day -case endourology operations. There is a common assumption \nthat patients would prefer to recover at home as part of a safe day -case pathway, however \nthis assumption is untested. This qu estion is particularly relevant for TURBT, TURP and TUEP \nbecause practice with respect to adoption of day -case surgery remains divergent across \nEngland. It is important to understand whether and how we can facilit ate an acceptable \npatient experience of day -case TURBT , TURP  and TUEP, so that our findings can inform \nfuture GIRFT recommendations around optimising day -case surgery pathways.  We intend to \nutilise a semi -structured qualitative interview  format  to explor e the patient experience of \nday case urology operations, and understand what contributes to a positive or negative \nexperience  (10). \nAims and Objectives  \nAim:\n\nSOURCE: Understanding the patient experience of day-case bladder tumour resection, and prostate resection or enucleation.pdf",
            "The interviews will be recorded. \nAfter, the research team will listen to the m to find common patient experiences. They will \nlook for ways that future patient\u2019s experiences could be made better.  \nResearch Question  \nWhat is the patient experience of  day-case TURBT, TURP and TUEP ?  \n \nRationale and background  \nResource constraints and evolving patient demographics mean that the waiting lists for \nelective surgery in the NHS are greater than ever. Nationally, the median average \npercentage of patients receiving transurethral resection of bladder tumour (TURBT) \ntreatment within 62 days of referral is only 13.1% (1). For patients requiring surgical \ntreatment for acute urinary retention, the median average national hospital wait time \nexceeds five months  (1).\n\nSOURCE: Understanding the patient experience of day-case bladder tumour resection, and prostate resection or enucleation.pdf"
        ]
    },
    "answer_relevancy":{
        "0":0.935677045,
        "1":0.9925595167,
        "2":0.9997008941,
        "3":0.9459678997,
        "4":0.7756477621,
        "5":0.9128911747,
        "6":0.8629223405,
        "7":0.9724578041,
        "8":0.9440674609,
        "9":0.9637743681,
        "10":0.983346722,
        "11":0.9467115976,
        "12":0.9502478011,
        "13":0.9446469869,
        "14":0.8722266791,
        "15":0.9472501393,
        "16":0.9662618882,
        "17":0.9629152105,
        "18":0.0,
        "19":0.9556858401,
        "20":0.0,
        "21":0.8228169543
    },
    "faithfulness":{
        "0":1.0,
        "1":1.0,
        "2":0.8571428571,
        "3":1.0,
        "4":1.0,
        "5":1.0,
        "6":1.0,
        "7":1.0,
        "8":1.0,
        "9":1.0,
        "10":1.0,
        "11":1.0,
        "12":1.0,
        "13":1.0,
        "14":0.875,
        "15":1.0,
        "16":1.0,
        "17":0.9,
        "18":null,
        "19":1.0,
        "20":null,
        "21":1.0
    },
    "context_recall":{
        "0":1.0,
        "1":1.0,
        "2":1.0,
        "3":1.0,
        "4":0.25,
        "5":1.0,
        "6":1.0,
        "7":1.0,
        "8":1.0,
        "9":0.0,
        "10":0.0,
        "11":0.3333333333,
        "12":0.3333333333,
        "13":1.0,
        "14":1.0,
        "15":1.0,
        "16":1.0,
        "17":0.6666666667,
        "18":1.0,
        "19":1.0,
        "20":0.2,
        "21":0.75
    },
    "context_precision":{
        "0":0.8333333333,
        "1":1.0,
        "2":1.0,
        "3":1.0,
        "4":1.0,
        "5":1.0,
        "6":1.0,
        "7":1.0,
        "8":1.0,
        "9":1.0,
        "10":0.5,
        "11":1.0,
        "12":0.0,
        "13":0.8333333333,
        "14":1.0,
        "15":1.0,
        "16":1.0,
        "17":1.0,
        "18":1.0,
        "19":1.0,
        "20":1.0,
        "21":1.0
    },
    "answer_correctness":{
        "0":0.8091733461,
        "1":0.7401492581,
        "2":0.6928528032,
        "3":0.4665767578,
        "4":0.5708386178,
        "5":0.8519282774,
        "6":0.7424650445,
        "7":0.865747341,
        "8":0.5415914695,
        "9":0.67378483,
        "10":0.6186290823,
        "11":0.7901455502,
        "12":0.7586575274,
        "13":0.768179555,
        "14":0.7908552502,
        "15":0.7220373605,
        "16":0.6154236218,
        "17":0.7415016918,
        "18":0.2170012526,
        "19":0.5425637301,
        "20":0.2301697225,
        "21":0.8994846141
    },
    "answer_similarity":{
        "0":0.9866933845,
        "1":0.9604313785,
        "2":0.9453242563,
        "3":0.8662830938,
        "4":0.950021138,
        "5":0.9531676552,
        "6":0.9698176084,
        "7":0.962970167,
        "8":0.966365878,
        "9":0.9304334375,
        "10":0.9744670936,
        "11":0.9105822007,
        "12":0.8528119277,
        "13":0.9727182198,
        "14":0.9137663257,
        "15":0.8881494418,
        "16":0.9616944872,
        "17":0.9660067672,
        "18":0.8680453531,
        "19":0.9698465933,
        "20":0.9207018236,
        "21":0.9579384562
    }
}